Technical Analysis for URGN - UroGen Pharma Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Fell Below 20 DMA | Bearish | 2.39% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.42% | |
| NR7 | Range Contraction | -0.42% | |
| Inside Day | Range Contraction | -0.42% | |
| 20 DMA Support | Bullish | -2.62% | |
| Crossed Above 20 DMA | Bullish | -1.53% | |
| Calm After Storm | Range Contraction | 3.06% | |
| 20 DMA Resistance | Bearish | -0.77% | |
| Calm After Storm | Range Contraction | -0.77% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| 20 DMA Resistance | 2 days ago |
| 10 DMA Resistance | 2 days ago |
| Up 3% | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 05/09/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Botulinum Toxin Oab Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.13 |
| 52 Week Low | 8.69 |
| Average Volume | 359,022 |
| 200-Day Moving Average | 15.16 |
| 50-Day Moving Average | 15.78 |
| 20-Day Moving Average | 14.00 |
| 10-Day Moving Average | 14.29 |
| Average True Range | 0.93 |
| RSI (14) | 46.24 |
| ADX | 13.23 |
| +DI | 19.05 |
| -DI | 22.92 |
| Chandelier Exit (Long, 3 ATRs) | 12.87 |
| Chandelier Exit (Short, 3 ATRs) | 15.17 |
| Upper Bollinger Bands | 15.14 |
| Lower Bollinger Band | 12.86 |
| Percent B (%b) | 0.57 |
| BandWidth | 16.31 |
| MACD Line | -0.35 |
| MACD Signal Line | -0.46 |
| MACD Histogram | 0.1092 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.10 | ||||
| Resistance 3 (R3) | 15.05 | 14.68 | 14.94 | ||
| Resistance 2 (R2) | 14.68 | 14.44 | 14.71 | 14.88 | |
| Resistance 1 (R1) | 14.42 | 14.29 | 14.55 | 14.47 | 14.83 |
| Pivot Point | 14.05 | 14.05 | 14.12 | 14.08 | 14.05 |
| Support 1 (S1) | 13.79 | 13.81 | 13.92 | 13.84 | 13.47 |
| Support 2 (S2) | 13.42 | 13.66 | 13.45 | 13.42 | |
| Support 3 (S3) | 13.16 | 13.42 | 13.36 | ||
| Support 4 (S4) | 13.21 |
